Fractyl Health, Inc. Common Stock 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Fractyl Health reported second quarter 2026 financial results with research and development expenses of $13.8 million, down from $21.2 million in the same period in 2025, primarily due to reduced spending on their Revita and Rejuva programs.
- General and administrative expenses were $5.3 million, up from $4.9 million in 2025, driven by higher stock compensation expense.
- The net loss for Q2 2026 was $25.5 million, an improvement from $27.9 million in Q2 2025, due to a $7 million reduction in operating expenses partially offset by a $5.1 million higher non-cash loss from warrant liabilities.
- Adjusted EBITDA improved by $7.7 million to -$16.3 million compared to -$24 million in Q2 2025.
- Cash and cash equivalents totaled $47.1 million as of June 30, 2026, with a runway extending into early 2027, beyond the anticipated pivotal data readout and potential de novo submission.
- Fractyl presented one-year randomized sham-controlled data showing Revita patients maintained over 80% of prior GLP-1 induced weight loss versus 46% in the sham arm, with no serious adverse events related to the device or procedure.
- The pivotal REMAIN 1 study completed randomization with over 300 participants and is powered above 95% for both co-primary endpoints; topline six-month data is expected in early Q4 2026 and 12-month data in Q1 2027.
- Fractyl received clinical trial authorization in the Netherlands and Ethics Committee approval in Australia for Rejuva 001, a gene therapy for type 2 diabetes, with dosing expected soon and preliminary data anticipated in the second half of 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good afternoon, and welcome to Fractyl Health's second quarter 2026 financial results and business update call. As a reminder, this conference call is being recorded. At this time, all participants are on listen-only mode. There will be a Q&A session following management's prepared remarks. I will now turn the call over to Brian Luque, Head of Investor Relations and Corporate Development at Fractyl. Brian, you may now begin.
Thank you. This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractyl.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer, and Lara Smith Weber, Chief Financial Officer. During this call, we make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements, even if subsequent events cause the company's views to change.
It is now my pleasure to pass the call over to Harith.
Thank you, Brian. Good afternoon, everyone. Nearly 30 million Americans are now on GLP-1 therapy. Approximately 1 million are discontinuing each month. What happens after discontinuation is now well-characterized. On average, patients regain roughly 60% of their prior weight loss within 12 months of stopping therapy, and cardiometabolic benefits begin to erode even earlier. For many patients, the choice is either to resume chronic pharmacotherapy or accept substantial weight regain. We believe Revita has the potential to offer a third option, durable drug-free weight maintenance following a one-time endoscopic procedure. A year ago, that was our thesis. Now, we have the first randomized sham-controlled evidence supporting that thesis one year after GLP-1 discontinuation and the most direct read-through to the REMAIN-1 pivotal cohort expected in early Q4. On our last three calls, I laid out four pillars that give us conviction in Revita. First, the clinical signal is real.
Second, our pivotal study is built to win. Third, there is a clear path to commercial value. Fourth, we are funded through definitive data later this year. Let me take each of them in turn, but I will spend most of my time on the commercial opportunity today. Pillar one, the clinical signal is real. On July 15, we reported one-year randomized data from the REMAIN-1 midpoint cohort. The study asked a simple question. One year after stopping a GLP-1 therapy, how much of the weight loss do patients keep? Revita patients maintain more than 80% of their prior GLP-1 induced weight loss at one year, compared with 46% in the sham arm. The treatment effect held from month 6 through month 12 under maintained blinding in a cohort where not one patient reinitiated GLP-1 therapy.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring